Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli ...

Regeneron (NASDAQ: REGN) is testing its drug, trevogrumab, along with Wegovy and another treatment, garetosmab, in a ...

Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

A team of scientists from the California Institute of Technology (Caltech) has developed a novel type of minuscule robot for targeted drug delivery, according to a research paper published recently in ...

Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.

Despite heavy demand for its weight-loss and diabetes treatments, limited supply hobbled Eli Lilly's fourth-quarter sales.

Nick Scali reported its 1H25 results, with a mixed bag of takeaways Let's dive in. Major US benchmarks finished mixed, with ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...